major adverse cardiovascular events

Overview

Major adverse cardiovascular events (MACE) is a clinical metric used to capture serious cardiovascular outcomes in a single composite endpoint. Although the exact components can vary by study, MACE commonly includes events such as myocardial infarction, stroke, and cardiovascular death, and in some settings may also incorporate all-cause mortality or other ischemic outcomes. It is widely used in cardiovascular research because it provides a standardized way to measure overall event burden across populations with cardiovascular disease, acute coronary syndrome, heart failure, diabetes, obesity, atrial fibrillation, and related conditions.

As a composite endpoint, MACE is not a biological molecule or therapeutic target itself, but a trial and cohort outcome used to quantify risk reduction, prognosis, and treatment effectiveness. In modern clinical research, MACE is frequently assessed in studies of antithrombotic therapy, glucose-lowering agents, lipid-lowering treatment, vaccines, and risk prediction models, often alongside hazard ratio, propensity score matching, Cox proportional hazards model, and other epidemiologic methods. Its interpretation depends on the population studied and on the specific event definitions used for myocardial infarction, ischemic stroke, cardiovascular mortality, and related endpoints.

Recent Publications Summary

Recent publications have examined major adverse cardiovascular events (MACE) across a wide range of clinical contexts, including retrospective validation of automated event ascertainment, population-based drug safety and effectiveness studies, registry analyses, and disease-specific cohort studies. One multisite study compared four electronic medical record retrieval approaches, including a zero-shot large language model workflow, against manual chart adjudication for identifying cardiovascular events and a composite MACE outcome in two adjudicated cohorts 42595369Aug. Other studies evaluated MACE as a principal effectiveness endpoint for tirzepatide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease, and for adjuvanted RSVPreF3 vaccination among US adults aged 60 years or older with underlying cardiovascular disease 42556854Aug42492842Jul.

Several cohort studies focused on incidence and prognosis. In Ethiopia, a retrospective cohort of patients discharged after acute coronary syndrome found that 33.8% experienced at least one MACE during follow-up, with a median time to event of 1.5 years; female sex and chronic comorbidities were associated with higher risk 42498465Jul. In Sjögren’s disease, a prospective multicenter cohort reported 17 MACE events over a median 9.5 years, including stroke, myocardial infarction, and cardiovascular death, and assessed associations with traditional and disease-specific risk factors as well as all-cause mortality 42223667Jun. A machine learning study in chronic heart failure similarly aimed to predict major adverse cardiovascular and cerebrovascular events (MACCE), underscoring the use of event composites in risk stratification research 42286995Jun.

Registry and real-world studies also used MACE to track outcomes after cardiovascular interventions and chronic therapy. In the SwissTAVI Registry, one-year MACE, defined as all-cause mortality, non-fatal myocardial infarction, and non-fatal stroke, declined over successive time periods in a large nationwide transcatheter aortic valve implantation cohort 42298270Jun. In the ETAF-TR registry of edoxaban-treated patients with atrial fibrillation, MACE was included among prespecified outcomes assessed across age groups 42455491Jul. Another study used a target trial emulation in REPRIEVE to estimate the risk of obesity, diabetes, hypertension, and MACE after switching to an integrase inhibitor in people with HIV at low-to-moderate cardiovascular risk 41911941Mar.

What Changes, What Holds

1. Automated event retrieval may make MACE ascertainment scalable without abandoning adjudication as the reference standard
METHOD Zero-shot large language model workflows and other electronic record retrieval approaches are being tested against manual chart review to identify cardiovascular events and composite MACE, which changes how the endpoint can be measured rather than what MACE means biologically. The established account of MACE as a composite outcome stands, but the paragraph suggests a practical shift toward semi-automated ascertainment in adjudicated cohorts 42595369Aug.

2. MACE remains a prognostic endpoint across very different diseases and interventions
REINFORCES tirzepatide and RSV vaccination studies, along with cohort work in acute coronary syndrome and Sjögren’s disease, use MACE exactly as the Overview describes: a composite outcome for quantifying risk, prognosis, and effectiveness across diabetes, cardiovascular disease, and other clinical settings 42556854Aug42492842Jul42498465Jul42223667Jun. The new work sharpens the baseline by showing that the endpoint continues to be portable across conditions, not that its meaning has changed.

3. MACE is now being tracked more explicitly in registry and emulation studies of procedures, anticoagulation, and HIV therapy
REINFORCES SwissTAVI, ETAF-TR, and REPRIEVE all use MACE as part of real-world outcome assessment, extending the baseline’s point that the metric is widely used in cardiovascular research and epidemiology 42298270Jun42455491Jul41911941Mar. Nothing here overturns the settled account; instead, the paragraph broadens the range of settings in which the same composite endpoint is being applied and compared.

Overview update candidates: automated MACE ascertainment with large language model workflows; continued use of MACE as an endpoint in tirzepatide; RSV vaccine; registry; and target-trial emulation studies.